)
Visual
test
Everest Medicines
Everest Medicines (1952) investor relations material
Everest Medicines 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary15 Jan, 2026
Strategic vision and company overview
Aims to become a leading integrated biopharma company in China, leveraging both near-term revenue growth and long-term sustainability through in-licensing and proprietary discovery.
Commercially launched three products and employs about 800 people, mostly in China.
Built a robust discovery platform and manufacturing facility to support end-to-end drug development.
Commercialization and product pipeline
Focuses on dual-engine growth: in-house R&D and in-licensing, with a strong commercial platform (AMMS) for innovative pharmaceuticals in China.
Nefecon, for IgA nephropathy, achieved RMB 1.2–1.4 billion sales guidance for 2024 and is the first non-oncology product to exceed RMB 1 billion in NRDL sales in its first year.
Velsipity, targeting ulcerative colitis, is approved in Macau and Singapore, with Mainland China approval expected soon and NRDL coverage targeted for 2027.
Recent in-licensing and CSO deals expand the portfolio into cardiovascular and ICU therapeutics, adding significant incremental revenue.
R&D and innovation focus
Early discovery pipeline emphasizes mRNA therapeutics and a proprietary BTK inhibitor (EVER001/civorebrutinib) showing promising results in renal diseases.
EVER001 demonstrated sustained autoantibody and proteinuria reduction, with plans for pivotal studies and basket trials in multiple indications.
mRNA platform features end-to-end capabilities, with lead programs in in vivo CAR-T and cancer vaccines, aiming for U.S. IND filing in the first half of 2026.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebCPT
2025 results beat guidance; Sun Belt focus, asset sales, and share buybacks drive 2026 strategy. - 6 FebCRI
Q1 2025 saw record revenue, a return to profit, and strategic spin-offs for future growth. - 6 FebCRIH1 2025 saw a return to profit, record revenues, and strong cash from major space projects.
- 6 FebSCW
Q2 2025 revenue up 120% y/y, driven by record Asian contract and backlog growth. - 6 FebSCWRevenue up 89% y/y, record backlog, and new strategy for European optical payload leadership.
- 6 FebSCWQ2 2024 revenue up 115% y/y, backlog nearly doubled, driven by major space contracts.
- 6 FebSCWSpace segment drives 29% revenue growth, strong backlog and contracts support 2025 outlook.
- 6 FebSCW73% revenue growth, record backlog, and major space contracts drive expansion and investment.
- 6 FebPENG
All proposals passed, with no questions raised and results to be filed on Form 8-K. - 6 FebSCWQ1 2025 revenue surged 97% year-over-year, with strong backlog and new contracts secured.
Next Everest Medicines earnings date
H2 202525 Mar, 2026
Everest Medicines
Next Everest Medicines earnings date
H2 202525 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Everest Medicines Limited is a biopharmaceutical company focused on the development, manufacturing, and commercialization of innovative medicines. The company specializes in therapies for infectious diseases, autoimmune disorders, and oncology. It partners with global biotechnology firms to bring advanced treatments to markets in China and other Asian regions. The company is headquartered in Shanghai, China, and its shares are listed on the Hong Kong Stock Exchange (HKEX).
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage